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Abstract Genetic discrimination in the context of genetic
testing has been identified as a concern for symptomatic and
asymptomatic individuals for more than three decades.
Genetic counselors are often the health care professionals
who discuss risks and benefits of genetic testing with patients,
thereby making them most appropriate to address patient con-
cerns about genetics and personal insurance (i.e., life, life as
related to mortgage or group insurance, disability, critical ill-
ness and travel). A pilot study was conducted to ascertain the
current practices of Canadian cancer genetic counselors in
regard to their discussions with patients about genetic testing
and access to personal insurance. Among the 36 counselors
surveyed, 100 % reported discussing the issue of genetic test-
ing and personal insurance with their patients. Several factors
influenced the content, depth and length of these discussions
including age, cancer status, family members, and patients’
current and future insurance needs. Counselors reported
discussing with patients the possible impact of genetic test
results on access to personal insurance, possible access and
use of patient genetic information by insurance companies,
and whom patients should contact if they have additional
questions. The most commonly reported inquiries from pa-
tients included questions about the possible impact of genetic
testing on their ability to obtain insurance, and the insurability
of family members.While 28% of counselors reported having
been contacted by an insurer requesting access to patient
information, only one counselor was aware of or could recall
the outcome of such a request. This pilot study revealed that
issues concerning genetics and personal insurance are com-
monly discussed in Canadian cancer genetic counseling ses-
sions. Counselors furthermore expressed a need for additional
educational resources on the topic of genetics and personal
insurance for themselves and their patients.
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Introduction
The use of genetic information by third parties for non-
therapeutic purposes is one of the major risks associated with
genetic testing and genetic research (Huizenga et al. 2010;
Joly et al. 2010; Taylor et al. 2008). The phenomenon of
genetic discrimination (hereafter BGD^) was introduced in
scientific literature in the 1980s. One of the first empirical
studies on the topic by Billings et al. (1992) suggested that
symptomatic and asymptomatic individuals receiving genetic
counseling services could be at risk for GD. The study defined
GD as Bdiscrimination against an individual or against mem-
bers of that individual’s family solely because of real or per-
ceived differences from the ‘normal’ genome of that
individual^ (Billings et al. 1992, p. 477). Since then, several
definitions of GD integrating concepts from various fields of
academic expertise (e.g., scientific, legal, ethical, and actuar-
ial) have been proposed (Joly et al. 2013).
Interestingly, the significant concerns raised by GD might
not be proportionate to actual risk. Documented incidents of
coverage denial, or increased premiums on the basis of genetic
information remain limited to a few relatively well known,
highly penetrant, familial, adult-onset, genetic conditions
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(Joly et al. 2013). Nonetheless, some patients decline to un-
dergo clinical genetic testing (Armstrong et al. 2003; Godard
et al. 2007), seek genetic counseling services (Bower et al.
2002; Geer et al. 2001), or participate in genetic research
(Kirkland et al. 2009) because of insurability concerns related
to GD. To address these concerns, many countries have
adopted laws or moratoria to prevent insurers from accessing
genetic information (Rothstein and Joly 2009).
In the United States (US), the Genetic Information
Nondiscrimination Act (GINA) was adopted in 2008 to pro-
hibit GD in health insurance and employment (Rothstein
2009). Aware of the limited scope of this Act, the U.S.
National Society of Genetic Counselors (NSGC) issued
Cancer Practice Guidelines, which recommend that the possi-
bility of GD be discussed during cancer genetic testing ses-
sions to promote informed consent (Hadley et al. 2003). The
NSGC has also recommended that patients be informed of the
limitations of GINA in addressing potential GD impacts on
access to life, long-term, and disability insurance.
In Canada, where no specific law addressing GD has been
enacted, studies have focused on patients’ perspectives on GD
in the context of highly penetrant, familial, adult onset, con-
ditions with a significant medical impact such as Huntington
disease (Bombard et al. 2007, 2009, 2012) and avenues for
policy reforms (Phoenix Strategic Perspective Inc. 2013;
Riley et al. 2012). More recently, a privacy survey prepared
for the Office of the Privacy Commissioner of Canada report-
ed that if recommended to undergo genetic testing, 52 % of
Canadians would be very concerned they might be asked to
provide test results for non-health related purposes, such as
insurance or employment (Phoenix Strategic Perspective Inc.
2013). Although the Canadian and US healthcare systems
differ, GINA revitalized the Canadian debate on access to
genetic information and may influence policy makers at the
federal and provincial level to propose similar anti-GD bills
(e.g., Proposition of a Genetic Non-Discrimination Acts) (Bill
127 2013; Bill S-201 2013). It is in this politically charged
context that the Canadian Association of Genetic Counsellors
(CAGC) issued a position statement on GD. In this statement,
the CAGC Bsupports and encourages the immediate develop-
ment and implementation of legislation to protect the
Canadian public from unfair use of genetic test results or fam-
ily history^ (Canadian Association of Genetic Counsellors
2012).
Patients consider genetic counselors to be experts and value
their information and support, including how to improve com-
munication about genetics within their family, help to antici-
pate certain feelings and experiences from future events, and
clarify values underlying decisions and attitudes (Bernhardt
et al. 2000). In this role, genetic counselors will have to ad-
dress the issue of GD in pre-test counseling sessions.
Australian and US data support this claim, demonstrating that
genetic counselors discuss the possibility of GD with patients
(Barlow-Stewart et al. 2009; Hall and Rich 2000; Huizenga
et al. 2010; Wertz 1998–1999). Until now, the content of these
discussions in the Canadian context was largely unknown.
Our survey was meant to fill this important knowledge gap,
and had the following objectives: 1) explore the practices of
Canadian cancer genetic counselors regarding genetics and
patients’ access to personal insurance, 2) determine the factors
that influence discussions on this topic, 3) document GD con-
cerns among counselors and patients and 4) identify needs that
should be met to facilitate future discussions with patients.
Methods
Sample and Procedures
After receiving research ethics approval from the McGill
Faculty ofMedicine Research Ethics Board, the research team
recruited participants by contacting the CAGC and requesting
that our survey be sent to their membership via its electronic
mailing list (~N=317). Participants were required to complete
the survey within 5 weeks of receiving the initial invitation e-
mail and informed consent documents. They were reminded
through a second e-mail notification via the CAGC listserv
2 weeks following the initial invitation. To be considered eli-
gible for our study, participants were required to be full mem-
bers of the CAGC, currently practicing in Canada and work-
ing at least part-time in the field of cancer genetic counseling.
Full members not currently practicing in Canada, as well as
student members, were excluded. Participants were required
to have completed a master’s program in genetic counseling,
or to have achieved bachelors, masters or Ph.D. degrees in a
related field. Thirty-eight responses were received; however,
one participant who reported currently working in the United
Kingdom was excluded from the study. One respondent
consented, but did not answer any questions; therefore, the
total number of included respondents was 36.
Instrument Design
The survey (Appendix) was a semi-structured question-
naire containing both multiple choice and open-ended
questions. The survey included five demographic ques-
tions and 10 open-ended questions designed to assess cur-
rent practices of genetic counselors in regard to discussing
the issue of genetic tests and patients’ access to personal
insurance. The questions were formulated following a re-
view of the genetic counseling literature on genetics and
access to insurance. The Pfeffer et al. study, in which the
researchers conducted phone interviews with cancer ge-
netic counselors in the U.S. (Pfeffer et al. 2003), was
particularly helpful in designing the instrument.
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Data Analysis
The principal investigator (YJ) and study coordinator (ML)
collected the data, and all three authors (YJ, ML & INF) par-
ticipated in the analysis. Inductive thematic analysis was used
to analyze the data collected (Braun and Clarke 2006).
Themes were independently identified across the data set
and agreed upon by the authors, and discrepancies were re-
solved throughmajority vote. Codes were developed and were
used to organize findings into six broad themes: (1) factors
considered by genetic counselors, (2) information provided by
genetic counselors to patients with respect to genetics and
access to personal insurance, (3) level of comfort among coun-
selors discussing genetics and access to personal insurance,
(4) patient concerns as reported by genetic counselors, (5)
genetic counselors’ sources of information, and (6) risk of
insurers requesting patient information. Quantitative data
were tallied and graphed, however formal statistical analyses
were not conducted considering the small sample size.
Results
Genetic Counselors’ Demographic Information
Forty percent (12/30) of study participants reported practicing
exclusively in cancer genetics. Therefore, the majority of coun-
selors surveyed practiced in at least one other area, most of
which were in the adult settings (Table 1). The most common
work setting (86.2 %;25/29) was a university or academic set-
ting. Forty percent (12/30) of respondents indicated having
worked in the field for 1 to 4 years. The years of work experi-
ence ranged from less than 1 year to greater than 15 years.
Though all four Canadian regions (Atlantic, Central, Prairies
and West coast) were represented, Central Canada had the
highest geographical representation of counselors in our study.
Given that some provinces, such as Nova Scotia, have only one
genetics center, broad regional categories were chosen in order
to ensure anonymity of the participants. Although 80% (24/30)
of respondents indicated seeing an average of four or more
patients per week, they were not specifically asked about the
number of patients seen in the context of cancer genetics. For
this reason, the exact number of patients seen in this settingmay
be lower than reported, as only 40 % (12/30) of respondents
practice exclusively in cancer genetics.
Discussion of Genetics and Personal Insurance
All genetic counselors reported discussing the issue of genet-
ics and access to personal insurance with their patients (see
Table 2). In addition to reporting that they discuss insurance
with their patients, 42 % (15/36) of these respondents supple-
mented their answer with additional details. In this group,
counselors elaborated to indicate that they discuss the issue
with all their patients (47 %; 7/15), address this issue with all
patients considering testing (20 %; 3/15), or discuss personal
insurance issues with all unaffected patients undergoing pre-
dictive or asymptomatic testing (33 %; 5/15).
Factors Considered by Genetic Counselors When Discussing
Insurance
Genetic counselors all reported discussing the issue of insur-
ance with their patients. In addition, some counselors also




Area of practice (N=30)a









University or academic setting 25 86.2
Physician’s private practice 1 3.4
Public medical facility 5 17.2
Other 1 3.4
Region of Canada (N=30)
Atlantic 3 10.0
Central 16 53.3
West coast 3 10.0
Prairies 8 23.7
Years of practice (N=30)




15 or more 4 13.3






Participants were not required to answer all items, resulting in fluctuation
in sample size for each question
a Participants were asked to indicate all areas of practices and two partic-
ipants indicated two responses for work setting; therefore, total percent-
age appears greater than 100 %
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described a set of factors that influenced the length and depth
of their discussion and included: the patient’s age, whether the
patient already had a personal history of cancer, whether or not
the patient was eligible for testing, whether or not the patient
had children or siblings, and whether the patient was likely to
need insurance in the future. Other elements that impacted the
discussion were the patient’s desire for more information and
whether or not they were concerned about the effects of test
results on their insurability. As explained by a genetic
counselor:
What the exact conversation looks like really depends
on the context in which I’m seeing a patient (i.e., are
they affected with cancer, are they young and being seen
for predictive testing, etc.).
Throughout the questionnaire, it was more common for
counselors to mention discussing GD with patients who were
currently unaffected. For example:
I tend to do it more in the context of pre-symptomatic
testing. When a patient has already had cancer that in
itself has bigger impact on insurability than genetic
testing.
Information Genetic Counselors Provide to Their Patients
Types of Personal Insurance Most Referenced in
Discussions: When addressing the potential impact of test
results on patients’ insurability, 41 specific references to
certain types of insurance were made. These included life
insurance (19), disability insurance (8), mortgage related
insurance (5), travel insurance (5), critical illness (3), and
group insurance (1). Two counselors reported mentioning
health insurance and reassured patients this coverage
would not be affected.
Counselors also provided examples of insurance chal-
lenges that patients could expect. One counselor stated:
I typically discuss that genetic test results may impact
their ability to obtain certain types of insurance in the
future. I explain that this may include being denied a
new insurance policy or charged higher premiums for
a new policy if they are found to carry a pathogenic
mutation. Specific types of insurance I provide as exam-
ples include life insurance or disability insurance on a
mortgage. I explore with them how this may or may not
impact their decision about genetic testing.
Patients’ Disclosure of Information to Insurers: Genetic
counselors reported advising patients about their duty to dis-
close information to insurers.
While some counselors informed patients that they were
required to answer insurers’ questions honestly, most coun-
selors also reported advising patients that they were not re-
quired to disclose additional information beyond what in-
surers ask on their forms. Examples of how genetic counselors
perceive the patients’ disclosure requirements include:
Patients should carefully read policies for what ongoing
reporting is required but generally, one is only required
to answer honestly the questions that are asked.
I also emphasize the fact that no one is obliged to pro-
vide genetic testing information unless they are asked to,
Table 2 Genetic counselors’ responses to quantitative items
Responses Number of responses Percentage (%)




How often do patients initiate the conversation? (N=36)
Always 1 2.8
Most of the time 1 2.8
Some of the time 25 69.4
Seldom 8 22.2
Never 1 2.8
In general, how comfortable are you discussing genetics and access to
personal insurance with patients? (N=31)




Very uncomfortable 0 0
Is the issue of insurer’s potential access to medical records mentioned on




How would you qualify the risk of insurer requesting patients’ records, or
of patients having difficulty obtaining insurance, following genetic
testing? (N=29)
Very high 2 6.9
Somewhat high 8 27.6
Low 18 62.1
Almost non-existent 1 3.4
Have you ever been contacted by an insurer to provide genetic




Counselors were not required to answer all items, resulting in fluctuation
in sample size for each item
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and as far as I know, the question Bis there a genetic
condition in your family, or do you have an inherited
genetic condition^ is not a standard one for most com-
panies (yet).
Insurance companies WILL use genetic test to assess
their eligibility and cost. Families must answer all ques-
tions truthfully on their insurance applications, but are
not required to volunteer additional information that is
not requested.
Obligation to report it if the question is asked by an
insurer.
One counselor noted informing patients that failing to
answer questions on an insurance application form truth-
fully could result in the insurance contract being
annulled.
The Impact of Family History vs. Genetic Testing: While
most genetic counselors advise their patients to secure
insurance before undergoing testing, they also discuss
the impact that a family history of cancer may have on
their insurability and that of their family members.
Numerous genetic counselors reported that their discus-
sion with patients who have a familial history of cancer
focuses on explaining that family history may have a
greater effect on insurance eligibility and premiums than
the results of a genetic test.
I stress that family history may determine insurance
rates, regardless of whether they choose to have genetic
testing or not.
Positive results may affect insurability, although family
history may also have an effect regardless of GT [(ge-
netic test)] results.
Also discuss that family history may often be as dam-
aging as genetic testing unless the history is quite re-
moved from them.
Their family history will have most significance to the
insurance company.
I feel fairly confident that personal and family history, if
striking, will trump any genetic information.
Information on Insurance Practice Additional comments
were made by some genetic counselors about the practices
of insurance companies in Canada:
I explain that although there have been initiatives to
prevent genetic discrimination in the U.S. and now in
Canada, there are still means for an insurance company
to decline a patient life insurance based on their genetic
risk. We have no guarantee that it will be a problem for
every individual.
We discuss that genetic tests are not something that all
companies integrate into their evaluation, nor in the
same way.
At some point our recommendations for appropriate
screening may conflict with insurance interests. For ex-
ample, even without genetic testing an insurance com-
pany would likely Bcatch on^ to increase familial risk if
they see a 30 year old who is getting annual breast MRI.
Insurance companies may investigate every part of a
patient’s health record. Insurance companies may not
insure unless the patient gets predisposition testing and
is negative.
Counselors also expressed being unsure how insurers
may incorporate genetic information into insurance
decisions:
Uncertainty in insurance coverage—uncertainty wheth-
er cancer syndromes are diseases (question asked about
disease in family)—Uncertainty whether a known mu-
tation in a parent/sibling is considered by insurance even
if [it is] not supposed to be used.—Uncertainty whether
a known mutation in oneself will impact insurance
decision.
Lack of definitive and shared standards between insur-
ance companies.
It is hard to predict how an insurance company would
view a personal cancer diagnosis vs. a diagnosis of a
hereditary cancer syndrome.
We don’t really know how insurance companies value
genetic test results.
Because all my information is anecdotal and because
each insurance company will ask different questions, I
really don’t know how this information may affect my
patients and their families now, or down the road.
Referral to Other Experts Genetic counselors reported ad-
vising patients to secure insurance before undertaking a genet-
ic test and to speak with other professionals when patients had
more questions. Fourteen counselors specified experts to
whom they refer their patients. Among these, 8 specifically
advised their patients to seekmore information from insurance
companies (including agents or brokers), 2 counselors men-
tioned referring patients to lawyers, and 1 advised that patients
should discuss this with their physician. Counselors express
referring patients in different ways:
To see if it [genetic test] would have an effect on existing
policies, [I advise them to] consult their broker.
If a patient is concerned at all, I advise that he/she con-
sult physician/lawyer/insurance agent to discuss further
before initiating genetic testing.
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I tell them there is a chance that they could be refused
insurance based on test results, but I’m no expert in the
matter, and if it’s something they feel very strong about
they should consult an attorney.
Only that it could be an issue and if [there are] concerns
to discuss with a broker.
I sometimes find I cannot answer their more specific
questions. When that’s the case, I typically encourage
patients to gather more information by contacting insur-
ance companies prior to having testing done.
Levels of Comfort Discussing GD
The level of comfort of counselors in discussing issues of
genetics and access to personal insurance with patients was
also explored. Overall, among the 31 counselors who shared
their level of comfort, 16 counselors reported feeling comfort-
able, 9 neutral and 5 uncomfortable. While no one reported
feeling very uncomfortable, 1 said feeling very comfortable
(Table 2; Fig. 1).
Although a large proportion of counselors 25/31 (79.8 %)
reported feeling comfortable or neutral discussing this issue
with patients, some stated they are often unable to answer
patients’ questions. For example, one counselor stated:
I feel somewhat comfortable discussing these issues
with patients, although, I sometimes find I cannot an-
swer their more specific questions. (Reported comfort
level: Neutral)
One genetic counselor reported feeling comfortable
discussing the issue with patients in spite of being unable to
answer specific questions:
Again, I can only tell patients general information that I
am familiar with. Details are specific to each person and
their own situation. For exploration of that, people need
to speak with a professional [with expertise in insur-
ance]. (Reported comfort level: Comfortable)
In contrast, 5/31 (16.6 %) of counselors revealed feeling
uncomfortable discussing the issue of access to personal
insurance with patients. One, who reported feeling uncomfort-
able, described lacking information in regard to the topic, as
well as experiencing a challenge in presenting information in a
balanced manner:
I do not feel like I have any real answers to patient
questions. Each individual’s plan may be different. This
is a common concern for patients referred to our clinic,
but I do not get much feedback from families whether or
not they actually did have trouble obtaining insurance. I
worry about balancing a potential financial risk vs the
medical benefit in knowing about cancer risks. (Report-
ed comfort level: Uncomfortable)
Some counselors pointed out they have a duty to address
the issue of genetics and personal insurance with patients re-
gardless of their professional ability to provide concrete
evidence:
I don’t know what concrete information to give patients
or even if I should be giving information to patients at
all. Even though I don’t know the facts, insurance is
something I feel I have a duty to bring up along with
other topics that patients may not otherwise think about
when considering genetic testing. (Reported comfort
level: Uncomfortable)
In addition, counselors made a point to let patients know
that they lack the expertise needed to fully address issues
related to genetics and insurability as seen in the following
two examples:
I reiterate that I am NOT an insurance expert.
If a patient asks me pointed questions I am quick to say
that I am not the best person to talk to as I have no
training on this subject.
Patient Concerns as Reported by Genetic Counselors
Counselors indicated that patients sometimes initiate the con-
versation about genetics and access to personal insurance.































Counselors level of comfort discussing genetic issues and access to personal insurance.
<1 Year
1 - 4 years 




level  of 
experience 
Fig. 1 Reported level of comfort
of counselors in discussing
genetics and patients’ access to
personal insurance. (N=30)a.
aOne counselor who reported
feeling comfortable did not
provide information regarding
years of experience
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about certain types of personal insurance including life insur-
ance (5/13), travel insurance (4/13), disability (2/13), critical
illness (1/13), and mortgage (1/13).
Counselors were asked to comment on the most common
questions and/or concerns expressed by patients with respect
to insurability. Almost 69 % (20/29) of counselors conveyed
that patients most commonly inquire about whether genetic
test results will impact their insurance eligibility and insurance
premiums. Additionally, 3 counselors described questions pa-
tients asked them concerning whether genetic test results
would impact their current insurance policies. This following
comment illustrates this concern:
Does having genetic testing mean I will not be able to
get insurance or will my current policy be cancelled?
Furthermore, surveyed counselors often communicat-
ed that patients were concerned about the potential im-
pact of their genetic test results on family members who
may seek personal insurance, including children and
siblings:
Will they be able to get insurance (this has included life,
disability, critical illness, and travel health insurance)?
Will it affect their children’s ability to get insurance? At
what point is there a risk to their children’s ability to
obtain insurance?
The results suggest that patients seek help from genetic
counselors to better understand the current practices of the
Canadian insurance industry. Three counselors noted patient
questions regarding the confidentiality, storage and disclosure
of genetic test results. As outlined in the following statements,
one respondent believed patients who decline a referral for
genetic counseling might do so out of fear for their
insurability:
I do not have numbers, but concern about insurance for
self or family seems to be a common reason that people
give if they decline a referral to our cancer genetics
program.
This is a common concern for patients referred to our
clinic, but I do not get much feedback from families
whether or not they actually did have trouble obtaining
insurance.
Counselors expressed difficulty in providing answers
to patients’ specific questions regarding insurance prac-
tices in Canada. More specifically, they were unable to
predict the likelihood of insurers requesting patient genet-
ic information, the rate of increased patient premiums, or
the degree of insurance coverage denials. In such cases,
one counselor reported:
I always fall back to the safest choice, which is, if con-
sidering purchasing insurance, do it before you know
what your genetic status is.
Genetic Counselor’s Sources of Information
Counselors reported relying on information gathered from
discussions with their colleagues, as well as past patient expe-
riences. Other sources of information they sought included
medical literature and professional reports (from institutions
such as the Canadian Actuaries Institute), personal experi-
ences, presentations from professional conferences, teaching
during their training programs, and websites (Table 3). Three
counselors conveyed they did not use any specific sources of
information.
One counselor who reported not using any specific sources
of information expressed, with others, a desire for access to
better resources as this issue can frustrate the consultation
process:
I wish I had access to better sources.
This is something I have expressed with colleagues that
we all need more info on. Most of us just seem to hand
wave and don’t have concrete documents/resources to
rely on or share with patients/families.
I feel there is extremely limited information and nobody
really knows anything and so the discussion is very
speculative. This makes it hard for patients to make
any kind of informed decision.
This question is good- it made me realize that a short
guide for GCs [Genetic counselors] would be very
helpful.
One counselor described using available literature on GD
from other countries as sources of information. A need for
specific resources on the issue of genetics and access to per-
sonal insurance for Canadian counselors was reported by three
other counselors throughout the study. One counselor
expressed that a short course was needed to further educate
genetic counselors on this issue.
Request for Patient Genetic Information from Insurers
Risk of Insurance Companies Requesting Genetic
Information Counselors in our study reported telling their
patients how little is known about how frequently insurance
companies request genetic test results, and how those results
may impact patient insurability.
I have never been requested to write a letter to a com-
pany on behalf of a patient, but can imagine how a
genetic counsellor’s letter could assist the company in
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making an accurate risk assessment (e.g., healthy patient
who carries a MLH1 mutation and is compliant with
annual colonoscopy).
When surveyed to qualify the risk of insurers requesting
patient information, 18/29 (62.1 %) counselors estimated it to
be low, 8/29 (27.6 %) find it somewhat high, 2/29 (6.9 %) very
high, and 1 (3.4 %) responded very low (Fig. 2).
Patients’ Consent to Insurers and General Practitioners’
Access to Their Genetic Results: Counselors were also
asked whether an insurer had contacted them to request patient
records. Eight of 29 respondents (27.6 %) reported an insurer
had contacted them under different circumstances (i.e., when a
patient was applying for insurance, or after a claim had been
submitted). Of these 8 counselors, one did not provide any
details on the specific incident, and another could not recall
the full circumstances. Two counselors reported being
contacted about neurogenetic patients, but not for cancer ge-
netic patients. One counselor described being contacted very
seldom, and most often for patients who tested negative for a
cancer predisposition gene:
Usually the patient has signed a consent form for the
insurer to get the records. It has mostly happened for
individuals proving that they do NOT have the condi-
tion in the family.
Another counselor described verifying that patients had
actually consented to have their results disclosed to the
insurer:
In all cases, the patients have provided the insurance
company with our program details, and I have always
double checked this request contacting the patient to
advise them that I had received such a request.
The majority of counselors (20/30; 66.7 %) stated that the
possibility that insurers could have access to patient genetic
data was not mentioned on the genetic test or the research
consent forms at their center.
Instances Where Counselors Were Requested to Provide
the Genetic Information of Patients: One counselor noted
being contacted by an insurer once in 10 years of practice.
This particular event involved an unaffected BRCA gene mu-
tation carrier, but no additional information was provided by
the counselor. Another counselor was asked to provide a letter
on behalf of a patient to indicate that genetic testing was not
offered due to the patient’s low risk of carrying a cancer pre-
disposition gene mutation. Another counselor shared being
contacted by insurers on several occasions, most often to ver-
ify a patient’s negative genetic test result. This counselor went
on to describe an event whereby both the patient, and the
family member were affected by the contact with an insurance




Discussions with other genetic counseling colleagues 11 Rely heavily on discussions that take place in the counseling
community (ex. through CAGC listserv)…
Patient experiences 10 Patients’ experience with insurance
Professional association conferences/presentations 7 Information from presentations by insurance brokers at recent
genetic counseling conferences.
Personal experiences 5 I have personal experience and anecdotal evidence.
Information during training program 5 … lectures from an underwriter during my training
Published reports/literature 4 Canadian genetics and life insurance task force report
No specific resources 3 I don’t have any sources of information that I rely on to inform
counselees about genetics and access to personal insurance.





















Perceived risk of insurers requesting a patient's record, or perceived difficulty
of patient obtaining insurance after genetic testing
Almost Nonexistant Low Somewhat High Very High
Fig. 2 Counselors’ perceived
risk of insurers requesting patient
information. (N=29)
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company. The details of the event are presented in the follow-
ing comment:
The original patient was being promoted at work, and in
the processing of her benefit package, they obtained her
consult[ation] letter from genetic counseling through the
GP files. The insurance provider communicated that
they would defer her processing until the results of her
genetic testing were confirmed. The mother [of this pa-
tient] was too afraid to ever come in for counseling and
testing, and the patient dropped out of communication
with our clinic.
The same counselor also described sending a letter on be-
half of a patient who was a PMS2 gene mutation carrier but
was believed to have a low penetrance allele.
In these examples, information on the patient’s insurance
outcome was unknown. Nevertheless, one counselor shared
the outcome of such an inquiry:
I was contacted by an insurance company because a
patient of mine had disclosed that she’d had an appoint-
ment with genetics (I don’t know if she volunteered this
information, or was asked outright).(…) I got in touch
with her [the patient] about this issue, and she asked me
to send a consult letter to the insurance company, to
reassure them that we did not feel her risk to develop
breast cancer was greatly increased over the population,
which I did. It seemed that information from our clinic
helped with her insurance application.
Discussion
This study explored the practices of Canadian cancer genetic
counselors regarding genetics and personal insurance. Our
results provide insight into Canadian cancer genetic coun-
selors’ perceptions regarding genetic testing and access to
personal insurance in the Canadian genetic counseling profes-
sion. Our results could also be used to better inform current
federal and provincial debates surrounding the need for a legal
protection against GD in Canada (Bill 127 2013; Bill S-201
2013).
Counselors were surveyed about (1) the factors they take
into consideration when discussing GD and insurance, (2) the
content of the information they provide to patients, (3) their
perspectives and level of comfort discussing GD, (4) patient
concerns, (5) their sources of information, and (6) requests
from insurers to access patient genetic information.
All 36 genetic counselors declared discussing issues related
to genetic information and access to personal insurance with
their patients, underlining that this particular topic is an im-
portant concern in their practice. This is consistent with
findings from a similar empirical study by Wham et al.
(2010), where 75 % of the 150 counselors surveyed declared
discussing risks of insurance or employer discrimination dur-
ing their initial cancer genetics consultation visits. The fact
that patients sometimes initiated such discussions may reflect
patients’ concerns about issues on genetics and access to per-
sonal insurance. This is consistent with the findings of other
studies describing the potential for GD in the context of insur-
ance before the adoption of specific legal protections against
GD in the US (Bower et al. 2002; Hall and Rich 2000).
Factors Considered by Genetic Counselors When
Discussing Insurance
All counselors reported a number of patient- and context-
specific characteristics influenced the depth and lengths of
their discussions with patients. These factors included the pa-
tient’s health and family status, need for insurance and indi-
vidual concerns. Our findings contrast with those from Pfeffer
et al. (2003), where only 16 % of surveyed NSGC counselors
mentioned taking into account patients’ characteristics as fac-
tors influencing the extent of their discussion on genetic dis-
crimination. We note however, that the Pfeffer et al. study was
based on a large US sample, and thus likely to reflect different
insurance concerns such as health insurance, particular to the
US context.
Information Provided by Genetic Counselors
Canadian counselors provide a range of information from
which five main subjects were identified: (1) the types of
insurance most referenced in discussions, (2) patient’s require-
ment to disclose information to insurers, (3) the potential im-
pact of family history in contrast with genetic test results, (4)
perspectives and information on insurance practice, and (5)
referral to other professionals.
Types of insurance referenced most in discussions
with patients
In the US, where health insurance is not universal, fear and
concerns of GD in the context of health insurance was an
important concern reflected through the adoption of GINA, a
legislation restricted to addressing GD in the contexts of
health insurance and employment (Hall and Rich 2000;
Ragoussis et al. 2014). However, in the Canadian context—
where health insurance is universal—it was not surprising to
find that genetic counselors discussed life insurance most with
patients. This finding is in line with current international con-
cerns about genetic discrimination in the context of life insur-
ance (Joly et al. 2013; Otlowski et al. 2012). Nonetheless, we
note that counselors reported travel insurance was the second
most cited type of insurance patients identified as source of
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concerns. This is a very interesting finding given the current
dearth of academic research on the use of genetic information
for this particular type of insurance contract.
Patient’s duty to disclose information to insurers
Counselors provided varying information on the duty of pa-
tients to disclose information to insurers. While most coun-
selors informed patients that they were required to answer the
insurers’ questions truthfully, some counselors defined this
duty to be limited to the insurance questionnaire by informing
their patients that they were not required to Bvolunteer^ genet-
ic information unless asked by the insurer. This interpretation
of the legal requirements of disclosure could mislead or be
misinterpreted by patients to mean that they are not required
to disclose all information that is material to their insurance
coverage eligibility (or insurability). Indeed, in Canada, a con-
tract for personal insurance is based on the principle of Bgood
faith^ (utmost good faith in Quebec civil law) whereby an
applicant is required to disclose Ball the facts known to him
which are likely to materially influence an insurer in the set-
ting of the premium, the appraisal of the risk or the decision to
cover it^ (Quebec Civil Code 1991, Art. 2408), while in turn,
the insurer is required to provide a coverage amount based on
the fair assessment of the applicant’s risk (Canadian Life and
Health Insurance Association Inc. 2010; Gregoire et al. 2009).
Applicants who fail to comply with this legal obligation risk
seeing their life insurance contract annulled by the courts at
the request of the insurer (Audet v. Industrielle-Alliance
(Quebec) 1990; Pfeffer et al. 2003). Therefore, while patients
may benefit from some information about insurance policies
applicable to genetic information (Trepanier et al. 2004),
counselors must be very cautious when discussing patients’
legal rights and obligations. Providing patients imprecise, in-
accurate or incomplete information could have legal repercus-
sion on patient’s insurance contracts, and could even result in
their policy being cancelled. We also note that the challenges
with counselors being aware and understanding the full re-
quirements and limitation of the laws within their jurisdiction
is not unique to Canada but has also been documented in the
US. For example, despite the adoption of GINA in the US,
many genetic counselors are still not fully aware of the law
and its limitations (Pamarti 2011).
Impact of family history of diseases in contrast with genetic
test results
Generally, counselors reported advising patients that family
history of diseases may have a greater impact on their insur-
ability than genetic test results. Indeed, detailed family histo-
ries of diseases have been considered an important source of
genetic information by insurers which, in some cases, may
constitute a more accurate prediction of future health than
the results of many current genetic tests (Hudson et al.
2007). It is interesting to note that some of the countries that
have adopted laws to restrict access to genetic test results still
authorize insurers to use information about family history for
underwriting (Lemmens 2004). The current Bill on Genetic
Discrimination (S-201) introduced in the Canadian Senate is
one example. It focuses on restricting access to information
from Bgenetic testing,^ but seems to exclude family history
from its scope of application (Bill S-201). Genetic counselors
should keep informed of legal developments on genetics and
insurance in Canada to better inform their patients (Trepanier
et al. 2004). This is especially important given the position of
the CAGC in favor of a legal protection against GD (Canadian
Association of Genetic Counsellors 2012).
Information on insurance practice
In our study, counselors commonly recommended that pa-
tients secure all insurance needs before undergoing genetic
testing. Indeed, the Canadian life and health insurance associ-
ation (CLHIA) stated that while they would not require appli-
cants to undergo genetic testing, they would seek access to
genetic test results whenever they have beenmade available to
the applicant or her/his physician (Canadian Life and Health
Insurance Association Inc. 2010). Nevertheless, as one coun-
selor mentioned, insurers may still be able to determine pa-
tients’ genetic profile based on other elements in their medical
records or family history. Genetic counselors were generally
uncertain about how insurers used genetic information when
assessing patients’ insurance coverage eligibility.
Referral to other professionals
Our findings indicate that counselors informed their patients
that they do not have expertise on issues concerning genetic
testing and personal insurance. Rather they recommended pa-
tients seek the assistance of other professionals including in-
surance agents, physicians, and lawyers. Given their vested
interest in using genetic information, insurance representa-
tives may not be a completely impartial source of information
for patients. Conversations with physicians and lawyers may
be more advantageous considering available confidentiality
and professional secrecy protections. Nevertheless, physi-
cians, like genetic counselors, may also lack the appropriate
expertise on personal insurance, and an attorney can be costly
even for a single consultation. This underlines an important
need for more training in this area, and a need for additional
resources for patients.
Genetics Counselors’ Source of Information
Our findings demonstrate that counselors would welcome ad-
ditional resources on genetics and personal insurance to
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facilitate their discussions with patients. As reported, most
counselors rely on their discussions with patients or col-
leagues as sources of information regarding genetics and per-
sonal insurance. Alternatively, some do not use any reliable
sources or use literature from foreign countries. While the use
of international literature may provide counselors with a glob-
al perspective on issues relevant to their practice, great caution
should be exercised as such informationmay not be applicable
to Canadian healthcare contexts. Indeed, countries have dif-
ferent conceptions of social, economic and human rights en-
titlement and have adopted a variety of approaches to address
concerns about genetics and personal insurance (Joly et al.
2010).
This pilot study highlighted an important knowledge
gap among genetic counselors, and identified a need to
provide genetic counselors with resources that include
more complete, accurate and accessible information on ge-
netics and personal insurance. This could take the form of a
pamphlet or a training course, which should include up-to-
date information on insurance underwriting practices, fa-
milial implications, summary data on the use of genetic
data for insurance in Canada, applicable laws and recent
policy developments. Based on the findings of this study
and the lack of available resources on this subject, we rec-
ommend that additional resources be developed for pa-
tients, which should seek to address the following four
main concerns: (1) the potential impact of genetic test re-
sults on insurability, (2) the patient’s duty to disclose in-
formation material to the insurer, (3) the state of the current
evidence on genetic discrimination, and (4) additional in-
formation as to whom to contact for supplementary infor-
mation or to discuss specific concerns.
Level of Comfort of Counselors Discussing Genetics
and Access to Personal Insurance
While genetic counselors acknowledged their limited
awareness of the policies and laws applicable to insurer’s
practices and expressed a need for additional resources,
they often reported feeling comfortable or neutral when
discussing these issues with patients. Although this may
at first appear contradictory, genetic counselors, like other
health care professionals, are often called to discuss with
their patients matters involving some degree of uncertainty
(Parascola et al. 2002). These conversations may include
uncertainty about whether or not a mutation will be detect-
ed, if patients will develop cancer, if they will be identified
as a carrier of a particular cancer predisposition or gene
mutation. However, the issue of genetic testing and insur-
ance carries significant legal implications that may be
overlooked or misinterpreted by counselors lacking appro-
priate knowledge or understanding of the law.
Patient Concerns as Reported by Genetic Counselors
According to counselors in our study, reports on patients’
concerns place travel insurance as the second most cited type
of personal insurance after life insurance. Issues concerning
travel insurance have been overlooked and may warrant fur-
ther exploration. This issue is especially pressing given that
travel insurance may be required not only for vacation travel,
but also to study or work abroad, both of which are considered
a growing competitive asset when seeking employment
(Calleja 2012; Stone and Petrick 2013).
Risk of Insurers Requesting Patients’ Information
The majority (18/29; 62.1 %) of Canadian cancer genetic coun-
selors surveyed estimated that the risk of insurers requesting
patient information or the risk that a patient would experience
difficulties obtaining insurance following genetic testing was
low. Nonetheless, 10/29 (34.5 %) perceive such risk to be
somewhat high or very high. These findings are lower than
results from studies conducted in the US. For example, in
2003 (before the adoption of GINA) as many as 82 % of
NSGC had estimated that such risk was low (Pfeffer et al.
2003), whereas a post-GINA survey reported that 94 % of
NSGC consider the risk of genetic discrimination to be low or
theoretical (Huizenga et al. 2010). Thus, it appears that
Canadian cancer genetic counselors have greater concerns
about their patients’ insurability risk than their American col-
leagues did before and after the adoption of GINA.
The risk that patients may be treated unfairly due to their
genetic test results is an ethical and professional challenge for
genetic counselors (Bower et al. 2002). Counselors’ perception
of GD risks may influence how they view coping strategies
against it (Bombard et al. 2013), the content of these discus-
sions with their patients (Pfeffer et al. 2003) or their level of
comfort discussing these issues. It is worth noting that, among
the 8 counselors who estimated the probability of an insurer to
request patients’ genetic information as somewhat high, 6 had
never been contacted by an insurer. The only counselor who
estimated this risk to be high reported never having been
contacted by insurers. These findings are in line with the con-
clusions drawn in a recent systematic review revealing that the
actual risk of GD in the context of life insurance is low, while
public concerns of this risk are substantial (Joly et al. 2013).
While 8/19 (28 %) of counselors reported having been
contacted by an insurer requesting access to a patient’s genetic
information, in only one instance were specific details about the
final outcome of such inquiry provided. Only one counselor
shared details of the contact, and that exchange with the insur-
ance company ultimately enabled the patient to secure insurance.
Greater knowledge of patients’ insurance outcomes following
insurers’ access to genetic data is needed in order to objectively
evaluate the real impact of genetic discrimination. Further
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studies in this regard are warranted. Considering current waitlists
for cancer genetic counseling across Canada, counselors’ work-
load is unlikely to allow them to document such requests and to
follow-up with patients concerning final outcome with insur-
ance. Yet, the CAGC could play an instrumental part in this
assessment by developing and maintaining a Canadian reposi-
tory to which patients could directly report when they are
experiencing difficulties obtaining and maintaining insurance
following genetic counseling services or genetic testing.
Currently in Canada, insurers are permitted to use relevant
genetic information in order to process coverage application
and claims. According to the CLHIA, insurers may seek ac-
cess to existing genetic test results when available to the pa-
tient or his physician (Canadian Life and Health Insurance
Association Inc. 2010, 2014). However, in order to obtain
personal health data, including genetic information, insurers
are required to seek the applicant’s consent, which is often
done through a data access and sharing clause included in
the insurance application form (Ngueng Feze and Joly
2014). Despite the fact that insurers may present counselors
with a patient’s written consent agreement to access their ge-
netic data, one counselor mentioned always contacting pa-
tients to ensure they were aware the request has been received,
and verified the patient’s consent before sending the informa-
tion. Another counselor mentioned that patients at their center
had the option of restricting access to their genetic data.
Previous findings attest to the ethical importance both coun-
selors and patients attribute to confidentiality, and associated
safeguards should be included in discussions with patients
(Bower et al. 2002; Trepanier et al. 2004).
Finally, the majority of counselors surveyed (20/30;
66.7 %) stated that the possibility of insurers’ accessing pa-
tient’s medical records (including genetic information) was
not mentioned on the genetic test and/or on the research con-
sent forms at their center. This may reflect an overall opinion
in the medical community that the risk of insurer’s requesting
such access is very low. Indeed, studies have demonstrated
that despite the lack of evidence of genetic discrimination in
Canada, Canadians in general, patients and research partici-
pants in particular, were likely to decline genetic testing when
informed of potential impacts to insurability (Godard et al.
2007; Phoenix Strategic Perspective Inc. 2013). An
Australian study came to similar conclusions, where the pro-
portion of participants who declined genetic testing among
those informed of insurance implications was more than dou-
ble the proportion among those without such knowledge
(Keogh et al. 2009). Access to genetic test results remains a
subject of debate in Canada. For example, while the Canadian
Institute of Actuaries states that Bif relevant genetic test results
are available to an individual applicant, the results must be
shared with the insurer in order to preserve the integrity and
proper functioning of the insurance mechanism^, the Office of
the Privacy Commissioner of Canada, which oversees the
Personal Information Protection and Electronic Documents
Act (PIPEDA) estimates that Bit is not clear that the collection
and use of genetic test results by insurance companies is de-
monstrably necessary, effective, proportionate or the least in-
trusive means of achieving the industry’s objectives at this
time^ (Canadian Institute of Actuaries 2014; Office of the
Privacy Commissioner of Canada 2014).
Considerations for Practice and Future Directions
Through this pilot study, genetic counselors clearly identified a
need to better understand the context and issues associated with
the use of genetic data by insurers to increase their knowledge
and better assist patients. Although genetic counseling sessions
may vary in content, depth and length, it is important that pa-
tients be provided with accurate and appropriate information
related to genetics and personal insurance that is consistent
across cancer genetic services. Such information is a pre-
requirement to ensure that patients can make an informed deci-
sion about undergoing genetic testing for hereditary cancers. Our
study identified a need for additional resources in order to im-
prove current practices. To this end, an additional course or
session on this issue could be incorporated in the genetic coun-
selors’ academic curriculum, on a recurring basis at conferences
or workshops at the CAGC’s meetings (or as part of an ongoing
continued professional education). Given that certain provinces
have a limited number of genetic counselors, identifying an
experienced counselor or another resource person within the
structure of the CAGC will provide access to valuable informa-
tion and support, especially for isolated practitioners. In addition,
a pamphlet or another type of information document presenting
background information and discussing current Canadian chal-
lenges on genetics and personal insurance could also be of as-
sistance to counselors, who could convey the information in
layman’s term to their patients during genetic counselling ses-
sions. The use of these additional tools should be monitored to
properly ascertain their usefulness and efficiency. Given that this
study focused on cancer genetic counselors and that most par-
ticipants also provide counseling in other genetic fields, it is
quite possible that all Canadian genetic counselors would stand
to benefit from the aforementioned additional resources.
Moreover, most counselors reported not knowing the out-
come of cases where insurers had requested access to the pa-
tient’s genetic information. This represents an important knowl-
edge gap, the improvement of which could assist counselors in
better understanding whether negative outcomes are frequent or
not. Thus, the CAGC could, with the consent of the patients,
monitor these situations and document the outcome of such
cases. This information could be aggregated with the national
association data or used as metrics in future GD studies.
Finally, this pilot study provided an appreciable sample of
qualitative data to be used as a foundation for larger Canadian
studies. An interesting element that was not assessed in our
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pilot study was where counselors received their training
(whether in Canada or abroad), in order to evaluate whether
this may have impacted their knowledge about personal insur-
ance. There is also a need to further explore counselors’
knowledge (including information needs), practice and con-
cerns related to the use of genetic information by other third
parties. For example, further studies could expand beyond
cancer genetics to include a broader range of counselors, and
incorporate mixed method study instruments including both
qualitative and quantitative data.
Limitations of the Study
Although this study is the first to focus on the views and expe-
riences of Canadian cancer genetic counselors, there are a few
limitations that should be taken into account when interpreting
our findings. First, this pilot represents a small sample size of
counselors, among whom many did not practice exclusively in
cancer genetic counseling. Therefore, the perception and prac-
tices of counselors who declined participationmay have differed.
The number of respondents is representative of cancer genetic
counselors in Canada, which make up a small community gen-
erally. Second, the study instrument requires further validity and
reliability testing. Since all data were self-reported, further qual-
itative or quantitative studies with larger populations of coun-
selors and patients could help to contextualize our findings and
improve survey design.
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Appendix
Study Instrument




If Yes, please specify
2. How often do patients initiate the conversation about
genetics and access to personal insurance?
a. Always
b. Most of the time
c. Some of the time
d. Very seldom
e. Never
3. What factor(s) do you consider when determining whether
or not to discuss genetics and access to personal insurance?
4. What information do you provide to your patients with
respect to genetics and access to personal insurance?
5. What source(s) of information do you rely on to inform
counselees about genetics and access to personal
insurance?
6. What are the most common questions and/or concerns
expressed by patients with respect to genetics and access
to personal insurance?
7. In general, how comfortable are you discussing genetics







8. Is the issue of insurers’ potential access to medical re-
cords mentioned on the genetic testing and/or research




9. How would you qualify the risk of insurers
requesting patients’ records, or of patient’s having
difficulty obtaining insurance, following genetic
testing?





10. Have you ever been contacted by an insurer to provide




If yes, please specify:
11. In what area(s), other than cancer genetics, do you prac-
tice? Please circle ALL applicable answers.







h. Specialty Clinic (please specify): ________________
12. Which of the following best describes your work setting?
a. University or academic health center
b. Private medical facility
c. Public medical facility
d. Physician’s private practice
e. Laboratory
f. Other (please specify): ______________
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